Artelo Biosciences ARTL

$ 1.17 0.88%

Quarterly report 2024-Q3
added 11-12-2024

Artelo Biosciences Balance Sheet 2011-2024 | ARTL

Annual Balance Sheet Artelo Biosciences

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-6.82 M	-12.1 M	-2.14 M	-4.42 M	-337 K	-573 K	-3.59 K	-17 K	-14.7 K	-	-	-
Long Term Debt	-	23 K	57 K	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	23 K	40 K	31 K	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	1.29 M	998 K	1.03 M	501 K	1.02 M	532 K	29.4 K	17.4 K	1.74 K	-	-	-	-
Total Liabilities	1.29 M	1.02 M	1.08 M	502 K	1.02 M	532 K	29.4 K	17.4 K	1.74 K	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-40.3 M	-31 M	-20.9 M	-9.47 M	-4.81 M	-2.64 M	-295 K	-60.2 K	-30.5 K	-15.3 K	-	-	-
Total Assets	13 M	20.4 M	28.3 M	4.38 M	6.48 M	397 K	574 K	3.59 K	17 K	14.7 K	-	-	-
Cash and Cash Equivalents	2.82 M	6.89 M	12.2 M	5.78 M	4.42 M	337 K	573 K	3.59 K	17 K	14.7 K	-	-	-
Book Value	11.8 M	19.4 M	27.2 M	3.87 M	5.46 M	-135 K	545 K	-13.8 K	15.3 K	14.7 K	-	-	-
Total Shareholders Equity	11.8 M	19.4 M	27.2 M	8.44 M	5.46 M	-135 K	545 K	-13.8 K	15.3 K	14.7 K	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Artelo Biosciences

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	78 K	-	-	-	-	-	15 K	23 K	32 K	-	-	57 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	775 K	1.03 M	817 K	1.29 M	921 K	609 K	840 K	1.02 M	512 K	567 K	924 K	1.08 M	593 K	-	718 K	-	501 K	-	-	-	-	-	-	-	-	-	-	-	-	342 K	32.9 K	10 K	17.4 K	17.4 K	17.4 K	3.3 K	1.74 K	1.74 K	1.74 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-46.4 M	-45.2 M	-42.8 M	-40.3 M	-37.2 M	-34.8 M	-33.2 M	-31 M	-27.7 M	-25.4 M	-22.9 M	-20.9 M	-16.9 M	-15 M	-19.5 M	-10.9 M	-9.47 M	-9.47 M	-9.47 M	-6.12 M	-4.81 M	-4.81 M	-4.81 M	-3.2 M	-2.64 M	-2.64 M	-2.64 M	-572 K	-295 K	-295 K	-572 K	-69.7 K	-60.2 K	-60.2 K	-60.2 K	-45.7 K	-30.5 K	-30.5 K	-30.5 K	-	-15.3 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	7.14 M	8.33 M	10.4 M	13 M	15.5 M	16.9 M	18.5 M	20.4 M	22.4 M	24.4 M	26.7 M	28.3 M	12.6 M	12.3 M	29 M	9.54 M	4.38 M	4.38 M	4.38 M	5.55 M	6.48 M	6.48 M	6.48 M	165 K	397 K	397 K	397 K	430 K	574 K	574 K	430 K	3.59 K	3.59 K	3.59 K	3.59 K	3.97 K	17 K	17 K	17 K	-	14.7 K	14.7 K	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	4.36 M	881 K	1.2 M	2.82 M	2.64 M	5.72 M	6.92 M	6.89 M	7.14 M	12.1 M	10.4 M	12.2 M	6.59 M	6.31 M	14 M	5.78 M	2.14 M	2.14 M	7.39 M	3.37 M	4.42 M	4.42 M	3.37 M	115 K	337 K	337 K	115 K	412 K	573 K	573 K	412 K	3.59 K	3.59 K	3.59 K	3.59 K	3.97 K	17 K	17 K	3.97 K	14.2 K	14.7 K	14.7 K	29.9 K	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	6.36 M	7.3 M	9.54 M	11.8 M	14.6 M	16.3 M	17.6 M	19.4 M	21.9 M	23.8 M	25.8 M	27.2 M	12 M	12.3 M	28.3 M	9.54 M	3.88 M	4.38 M	4.38 M	5.55 M	6.48 M	6.48 M	6.48 M	165 K	397 K	397 K	397 K	430 K	574 K	232 K	397 K	-6.46 K	-13.8 K	-13.8 K	-13.8 K	671	15.3 K	15.3 K	15.3 K	-	14.7 K	14.7 K	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	6.36 M	7.3 M	9.54 M	11.8 M	14.6 M	16.3 M	17.6 M	19.4 M	21.9 M	23.8 M	25.8 M	27.2 M	11.5 M	12.8 M	13.3 M	8.44 M	9.05 M	9.05 M	9.05 M	4.96 M	4.96 M	4.96 M	4.96 M	-475 K	-475 K	-475 K	-475 K	294 K	545 K	545 K	294 K	-6.46 K	-13.8 K	-13.8 K	-13.8 K	671	15.9 K	15.3 K	15.3 K	-	14.7 K	14.7 K	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency